{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:13:58Z","timestamp":1790900038689,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-024-04738-5","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T05:48:36Z","timestamp":1735796916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["DPYD genotype should be extended to rare variants: report on two cases of phenotype \/ genotype discrepancy"],"prefix":"10.1007","volume":"95","author":[{"given":"Paul","family":"Vilquin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Medard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauriane","family":"Goldwirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Mourah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4285-7067","authenticated-orcid":false,"given":"Evelyne","family":"Jacqz-Aigrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"4738_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1517\/14740338.2010.511610","volume":"9","author":"SE Mikhail","year":"2010","unstructured":"Mikhail SE, Sun JF, Marshall JL (2010) Safety of capecitabine: a review. Expert Opin Drug Saf 9:831\u2013841. https:\/\/doi.org\/10.1517\/14740338.2010.511610","journal-title":"Expert Opin Drug Saf"},{"key":"4738_CR2","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H, Zhao W et al (2021) Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis. Oncologist 26:1008\u20131016. https:\/\/doi.org\/10.1002\/onco.13967","journal-title":"Oncologist"},{"key":"4738_CR3","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/bcp.15715","volume":"89","author":"C Arriv\u00e9","year":"2023","unstructured":"Arriv\u00e9 C, Fonrose X, Thomas F et al (2023) Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors? Br J Clin Pharmacol 89:2446\u20132457. https:\/\/doi.org\/10.1111\/bcp.15715","journal-title":"Br J Clin Pharmacol"},{"key":"4738_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejca.2022.11.028","volume":"181","author":"MC Etienne-Grimaldi","year":"2023","unstructured":"Etienne-Grimaldi MC, Pallet N, Boige V et al (2023) Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency. Eur J Cancer 181:3\u201317. https:\/\/doi.org\/10.1016\/j.ejca.2022.11.028","journal-title":"Eur J Cancer"},{"key":"4738_CR5","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/bjc.2017.94","volume":"116","author":"D Meulendijks","year":"2017","unstructured":"Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N et al (2017) Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 116:1415\u20131424","journal-title":"Br J Cancer"},{"key":"4738_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM et al (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther 103:210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"key":"4738_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41416-023-02517-2","volume":"130","author":"G Le Teuff","year":"2024","unstructured":"Le Teuff G, Cozic N, Boyer JC et al (2024) Dihydropyrimidine dehydrogenase gene variants for predicting grade 4\u20135 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis. Br J Cancer 130:808\u2013818. https:\/\/doi.org\/10.1038\/s41416-023-02517-2","journal-title":"Br J Cancer"},{"key":"4738_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/cpt.2608","volume":"112","author":"M de With","year":"2022","unstructured":"de With M, Knikman J, de Man FM et al (2022) Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. Clin Pharmacol Ther 112:62\u201368. https:\/\/doi.org\/10.1002\/cpt.2608","journal-title":"Clin Pharmacol Ther"},{"key":"4738_CR9","doi-asserted-by":"publisher","unstructured":"White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Ackland S (2021) Ethnic diversity of DPD activity and the DPYD gene: review of the literature. Pharmgenomics Pers Med.;14:1603\u20131617. https:\/\/doi.org\/10.2147\/PGPM.S337147.","DOI":"10.2147\/PGPM.S337147"},{"key":"4738_CR10","unstructured":"Waters.https:\/\/www.waters.com\/waters\/fr."},{"key":"4738_CR11","unstructured":"Sophia Genetics\u2122 Community Panel for Pharmacogenomics https:\/\/www.sophiagenetics.com. Sophia Genetics"},{"key":"4738_CR12","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","volume":"74","author":"SM Offer","year":"2014","unstructured":"Offer SM, Fossum CC, Wegner NJ et al (2014) Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 74:2545\u20132554. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2482","journal-title":"Cancer Res"},{"key":"4738_CR13","doi-asserted-by":"publisher","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","volume":"12","author":"MC Etienne-Grimaldi","year":"2017","unstructured":"Etienne-Grimaldi MC, Boyer JC, Beroud C et al (2017) New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS ONE 12:e0175998. https:\/\/doi.org\/10.1371\/journal.pone.0175998","journal-title":"PLoS ONE"},{"key":"4738_CR14","doi-asserted-by":"publisher","first-page":"e2300599","DOI":"10.1200\/PO.23.00599","volume":"8","author":"ABP van Kuilenburg","year":"2024","unstructured":"van Kuilenburg ABP, Pleunis-van Empel MCH, Brouwer RB et al (2024) Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants. JCO Precis Oncol 8:e2300599. https:\/\/doi.org\/10.1200\/PO.23.00599","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"4738_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/bcp.15536","volume":"89","author":"M Maillard","year":"2023","unstructured":"Maillard M, Launay M, Royer B et al (2023) Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br J Clin Pharmacol 89(2):762\u2013772. https:\/\/doi.org\/10.1111\/bcp.15536","journal-title":"Br J Clin Pharmacol"},{"key":"4738_CR16","unstructured":"HAS. Haute Autorit\u00e9 de Sant\u00e9 Methodes de recherche d\u2019un d\u00e9ficit en dihydropyrimidine deshydrogenase visant a pr\u00e9venir certaines toxicites s\u00e9v\u00e8res associ\u00e9es aux traitements incluant une fluoropyrimidine (5-fluorouracile ou cap\u00e9citabine). https:\/\/www.has-sante.fr (accessed: March 23th 2024)"},{"key":"4738_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.therap.2016.09.014","volume":"72","author":"N Picard","year":"2017","unstructured":"Picard N, Boyer JC, Etienne-Grimaldi MC et al (2017) Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). Therapie 72:185\u2013192. https:\/\/doi.org\/10.1016\/j.therap.2016.09.014","journal-title":"Therapie"},{"key":"4738_CR18","unstructured":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines - PubMed. Accessed March 25 (2024) https:\/\/pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr\/31745289\/"},{"key":"4738_CR19","doi-asserted-by":"publisher","unstructured":"Chan TH, Zhang JE, Pirmohamed M (2023) DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: A systematic review. Published online 11; 23299813. https:\/\/doi.org\/10.1101\/2023.12.11.23299813","DOI":"10.1101\/2023.12.11.23299813"},{"key":"4738_CR20","doi-asserted-by":"publisher","first-page":"e2200508","DOI":"10.1200\/PO.22.00508","volume":"7","author":"F Poumeaud","year":"2023","unstructured":"Poumeaud F, Dalenc F, Mathevet Q et al (2023) Phenotype\/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report. JCO Precis Oncol 7:e2200508. https:\/\/doi.org\/10.1200\/PO.22.00508","journal-title":"JCO Precis Oncol"},{"key":"4738_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41416-020-0962-z","volume":"123","author":"N Pallet","year":"2020","unstructured":"Pallet N, Hamdane S, Garinet S et al (2020) A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. Br J Cancer 123:811\u2013818. https:\/\/doi.org\/10.1038\/s41416-020-0962-z","journal-title":"Br J Cancer"},{"key":"4738_CR22","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3390\/curroncol29030113","volume":"23","author":"BS Sheffield","year":"2022","unstructured":"Sheffield BS, Beharry A, Diep J et al (2022) Point of Care Molecular Testing: Community-Based Rapid Next-Generation Sequencing to Support Cancer Care. Curr Oncol 23:1326\u20131334. https:\/\/doi.org\/10.3390\/curroncol29030113","journal-title":"Curr Oncol"},{"key":"4738_CR23","doi-asserted-by":"publisher","unstructured":"Peruzzi E, Roncato R, De Mattia E et al (2023) Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? Br J Clin Pharmacol Published online November 5. https:\/\/doi.org\/10.1111\/bcp.15956","DOI":"10.1111\/bcp.15956"},{"key":"4738_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40246-023-00546-9","volume":"17","author":"E De Mattia","year":"2023","unstructured":"De Mattia E, Polesel J, Silvestri M et al (2023) The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity. Hum Genomics 17:99. https:\/\/doi.org\/10.1186\/s40246-023-00546-9","journal-title":"Hum Genomics"},{"key":"4738_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41397-023-00322-x","volume":"24","author":"R Larrue","year":"2024","unstructured":"Larrue R, Fellah S, Hennart B et al (2024) Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity. Pharmacogenomics J 24:1. https:\/\/doi.org\/10.1038\/s41397-023-00322-x","journal-title":"Pharmacogenomics J"},{"key":"4738_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.2069","volume":"109","author":"JE Knikman","year":"2021","unstructured":"Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar H, Henricks LM (2021) Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine\u2010Related Toxicity: What Are the Options? Clin Pharmacol Ther 109:591\u2013604. https:\/\/doi.org\/10.1002\/cpt.2069","journal-title":"Clin Pharmacol Ther"},{"key":"4738_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12885-023-10857-8","volume":"23","author":"DK Lau","year":"2023","unstructured":"Lau DK, Fong C, Arouri F et al (2023) Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre. BMC Cancer 23:380. https:\/\/doi.org\/10.1186\/s12885-023-10857-8","journal-title":"BMC Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04738-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04738-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04738-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T18:02:47Z","timestamp":1735840967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04738-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4738"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04738-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}